Part II: Influence of dimerization of a modified GnRH-I peptide sequence on a male antifertility vaccine

被引:6
作者
Ferro, VA
Harvey, MJA
Colston, A
Stimson, WH
机构
[1] Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland
[2] Univ Glasgow, Sch Vet, Dept Small Anim Clin Studies, Glasgow, Lanark, Scotland
关键词
antibodies; antifertility; cross-reactivity; C-terminal; dimer; GnRH-I immunoneutralization; N-terminal;
D O I
10.1034/j.1600-0897.2002.01121.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
PROBLEM: In the previous paper, we described how the tetanus toxoid (TT) conjugated monomer, CHWSYGLRPG-NH2, induced high neutralizing antibody titres, which resulted in decreased levels of testosterone and subsequent antifertility. However, its counterpart HWSYGLRPGC, induced low avidity antibody titres. We wanted to know whether peptide dimerization would improve the efficacy of both peptides. METHOD OF STUDY: Male Sprague-Dawley rats were immunized with modified dimerized GnRH-I peptides (HWSYGLRPGCCGPRLGYSWH and GPRLGYSWHCCHWSYGLRPG-NH2),with or without conjugation to TT. RESULTS: The unconjugated dimers were not effective in causing castration, although the first peptide dimer did induce production of antibodies. When conjugated to TT, both dimers showed the same level of efficacy in causing castration as each other. However, there were differences in antibody binding to native GnRH. CONCLUSIONS: Dimerization and conjugation to a carrier improved the antifertility efficacy of HWSYGLRPGC, whereas the conjugated monomer CHWSYGLRPG-NH2 showed a greater level of consistent castration than its conjugated dimer.
引用
收藏
页码:372 / 380
页数:9
相关论文
共 30 条
[1]   Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract [J].
Bowman, LM ;
Holt, PG .
INFECTION AND IMMUNITY, 2001, 69 (06) :3719-3727
[2]   Enhanced antigen-specific delayed-type hypersensitivity and immunoglobulin G2b responses after oral administration of viable Lactobacillus casei YIT9029 in Wister and Brown Norway rats [J].
de Waard, R ;
Garssen, J ;
Snel, J ;
Bokken, GCAM ;
Sako, T ;
in't Veld, JHJ ;
Vos, JG .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (04) :762-767
[3]  
Ferro V A, 1995, Ther Immunol, V2, P147
[4]  
Ferro V A, 1996, Drug Des Discov, V14, P179
[5]   Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer [J].
Ferro, VA ;
Stimson, WH .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) :1468-1478
[6]   Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine [J].
Ferro, VA ;
Stimson, WH .
VACCINE, 1998, 16 (11-12) :1095-1102
[7]  
Ferro VA, 1999, BIODRUGS, V12, P1
[8]   Immunoneutralisation of GnRH-I, without cross-reactivity to GnRH-II, in the development of a highly specific anti-fertility vaccine for clinical and veterinary use [J].
Ferro, VA ;
Khan, MAH ;
Latimer, VS ;
Brown, D ;
Urbanski, HF ;
Stimson, WH .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2001, 51 (02) :109-129
[9]   Immunological castration using a gonadotrophin-releasing hormone analogue conjugated to PPD [J].
Ferro, VA ;
OGrady, JE ;
Notman, J ;
Stimson, WH .
FOOD AND AGRICULTURAL IMMUNOLOGY, 1995, 7 (03) :259-272
[10]  
FERRO VA, 2002, IN PRESS AM J REPROD